BioSpace News Archive

Atea Pharmaceuticals, Inc. today provided an update on the company’s clinical development priorities for 2022, including broadening its portfolio to include Phase 2 programs across three severe viral diseases.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that Jean M. Casner joined the Company this week on January 3, 2022 as Senior Vice President & Chief Human Resources Officer.

AN2 Therapeutics, Inc. today announced several significant strides in the company’s development over the past year.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to Randy Anderson, Senior Vice President of Biometrics to purchase an aggregate of 130,000 shares of common stock.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the H.C. Wainwright BioConnect Virtual Conference from January 10th to January 13th.

Treace Medical Concepts, Inc. today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 4:30 p.m. Eastern Time.

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform, announced today that its Founder and CEO, José M. Mejía Oneto, M.D., Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 10 a.m. EST.

Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that Dr. Meina Liang has joined the company as Chief Technology Officer.

AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approvals for upadacitinib (RINVOQ®, 15 mg once daily) to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that Odonate is a “public shell” pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted.